Breckenridge Pharmaceutical Inc.
BOCA RATON, Fla. -- Breckenridge Pharmaceutical Inc. is a privately held pharmaceutical marketing, research and development company that has been in business for over 25 years.
The company markets a broad range of generic prescription products in many therapeutic categories, including the only authorized multisource versions of patented Sumalate-containing products. Ferrex 28, Ferrex 150 Plus, Ferrex 150 Forte Plus, Multigen, Multigen Plus and Multigen Folic, and Vinate PN Care all contain Sumalate pursuant to an exclusive license and supply agreement with Albion Laboratories. Breckenridge also has an exclusive license pact with Pare Labs to market Folbee, Folbic and Folbee Plus.
The company has introduced several ANDAs (abbreviated new drug applications), including its recent launch of vitamin D capsules, the generic version of Drisdol. Breckenridge entered into an agreement with Orit Laboratories to market its ANDA, and the companies launched the product in August.
Breckenridge also markets multiple ANDA products, including estradiol/norethindrone acetate tablets, 1 mg/0.5 mg (generic version of Activella); oxcarbazepine tablets (generic version of Trileptal); meloxicam tablets (generic version of Mobic); Ascomp with codeine (generic version of Fiorinal with codeine); butalbital, acetaminophen, caffeine and codeine phosphate (generic version of Fioricet with codeine); cyclobenzaprine (generic version of Flexerfl); methylprednisolone (generic version of Medrol); polyethylene glycol powder (generic version of Miralax); folic acid tablets; and prednisone 1-mg tablets.
The company has an aggressive product development program and is working on over 40 ANDAs, many of which are currently filed and pending Food and Drug Administration approval.
Breckenridge is also offered many development and marketing projects for products developed by other companies. The company has announced plans to collaborate with Chemo/Liconsa (Madrid), Helm A/G (Hamburg, Germany) and Orbus (Ontario, Canada), and has many more projects in various stages of due diligence with companies throughout the world. This will position Breckenridge for significant growth in the coming years.
Breckenridge markets over 100 products in various dosage forms, including tablets, capsules, soft-gel capsules, liquids and suspensions, as well as topical ointments, creams, gels and lotions.
"We bring many new products to market each year," a spokesman says. "Our line includes products in many therapeutic categories, including antihistamines, analgesics, prescription vitamin and mineral supplements, dermatologics, urinary antiseptics, anticholinergics/antispasmodics, and women's health.
"All our products are subject to an extensive quality control/quality assurance (QC/QA) program that satisfies all applicable FDA requirements."
Breckenridge Pharmaceutical, Inc.
1141 South Rogers Circle
Boca Raton, Fla. 33487
ANTHONY MIHELICH, Vice President of Corporate Development
Phone: (561) 443-3314
Fax: (561) 989-0819
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||RX/GENERIC DRUGS--Profiles|
|Publication:||Chain Drug Review|
|Article Type:||Company overview|
|Date:||Sep 28, 2009|
|Previous Article:||Greenstone LLC.|
|Next Article:||Sandoz Inc.|